Borislav Borissov
Overview
Explore the profile of Borislav Borissov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
21
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pochopien M, Dziedzic J, Aballea S, Clay E, Zerda I, Toumi M, et al.
J Mark Access Health Policy
. 2024 Apr;
12(2):35-57.
PMID: 38660414
Objective: Currently there are no disease-specific approved therapies for non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH); however, several treatments are under development. This study aimed to estimate the cost-effectiveness...
2.
Qiu T, Liang S, Wang Y, Dussart C, Borissov B, Toumi M
Front Public Health
. 2021 Dec;
9:754482.
PMID: 34900902
Some advanced therapy medicinal products (ATMPs) hold great promises for life-threatening diseases with high unmet needs. However, ATMPs are also associated with significant challenges in market access, which necessitates the...
3.
Ilieva K, Borissov B, Toumi M
J Mark Access Health Policy
. 2020 Dec;
8(1):1847808.
PMID: 33312456
: Gene therapy brings opportunities to discover cures for diseases for which there are no adequate treatments. As most gene therapies target rare diseases, several challenges are associated with their...
4.
Dabbous M, Milea C, Simoens S, Francois C, Dussart C, Chachoua L, et al.
J Mark Access Health Policy
. 2019 Sep;
7(1):1650596.
PMID: 31489151
: The Trump administration's 'American Patients First' blueprint proposes to reduce drug prices in the USA by increasing drug prices abroad, ex USA. The possibility of the Trump administration to...
5.
Jaroslawski S, Auquier P, Borissov B, Dussart C, Toumi M
J Mark Access Health Policy
. 2018 Nov;
6(1):1542920.
PMID: 30425804
We aimed to evaluate the rate of usage and the kind of patient-reported outcome (PRO) claims in orphan drug approvals from the European Medicines Agency (EMA) dated between 1/1/2012 and...
6.
Jaroslawski S, Auquier P, Borissov B, Dussart C, Toumi M
J Mark Access Health Policy
. 2018 May;
6(1):1433426.
PMID: 29785254
: Claims included in package inserts (PIs) for medicinal products approved by the US Food and Drug Administration (FDA) constitute the regulatory definition of drugs' benefits and risks. : We...
7.
Borissov B, Urbich M, Georgieva B, Tsenov S, Villa G
J Mark Access Health Policy
. 2018 Jan;
5(1):1412753.
PMID: 29321830
An elevated level of low-density lipoprotein cholesterol (LDL-C) constitutes one of the most important modifiable risk factors for cardiovascular disease (CVD). Individuals with heterozygous familial hypercholesterolaemia (HeFH) are particularly vulnerable...